statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

IO Biotech appoints Faical Miyara as CBO

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win...

IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer

IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 81,600 shares, a...

IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Growth in Short Interest

Evotec (OTCMKTS:EVTCY  Get Free Report) and IO Biotech (NASDAQ:IOBT  Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based...

Comparing IO Biotech (NASDAQ:IOBT) and Evotec (OTCMKTS:EVTCY)

Acciones al alza
SCWorx (NASDAQ:WORX) crecieron un 49,12% para establecerse en los 2,55 d lares durante la sesi n del after-market del mi rcoles.
IO Biotech (NASDAQ:IOBT) experimentaron un repunte...

12 acciones de salud en movimiento en la subasta de cierre del 06/03/2024

New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a...

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA (pembrolizumab), in patients with advanced melanoma...

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win...

IO Biotech to Present at 44th Annual Cowen Health Care Conference

IO Biotech, Inc. (NASDAQ:IOBT  Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling...

IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update

IO Biotech: A Phase 3 Company Getting No Respect...

IO Biotech: A Phase 3 Company Getting No Respect

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Volume	46,964.00
52-Wk High	$2.64
52-Wk Low	$0.8163

IOBT IO Biotech Inc

About

Feed

News

Earnings

Fundamentals